Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 32 holding rows worth $1,155,798,470.

Accession
0001831942-24-000002
Filed
2024-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2023

A holdings report, 32 entries on the cover page, a total value of $1,155,798,470 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,155,798,470 with VALUE read as dollars as filed, 13F file number 028-20976. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MERUS N VN5749R100COM4,747,373$130,552,758dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock2,167,793$99,848,546dollars as filed
NUVALENT INC COM670703107Stock1,331,037$97,951,013dollars as filed
VERA THERAPEUTICS INC92337R101COMMON STOCK5,450,000$83,821,000dollars as filed
RHYTHM PHARMACEUTICALS INC76243J105COM1,550,000$71,253,500dollars as filed
VAXCYTE INC COM92243G108Stock1,100,000$69,080,000dollars as filed
CABALETTA BIO INC12674W109COMMON STOCK1,900,000$43,130,000dollars as filed
IMMUNOVANT INC45258J102COM1,000,000$42,130,000dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM1,924,074$41,906,332dollars as filed
ARVINAS INC04335A105COM1,000,000$41,160,000dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW1,884,084$40,545,488dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock2,901,816$40,161,133dollars as filed
COGENT BIOSCIENCES INC19240Q201COM5,566,026$32,728,233dollars as filed
ALPINE IMMUNE SCIENCES INC02083G100COM1,610,000$30,686,600dollars as filed
SOLENO THERAPEUTICS INC834203309COM700,000$28,175,000dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW701,967$27,840,011dollars as filed
CELCUITY INC15102K100COM1,754,704$25,566,037dollars as filed
RAYZEBIO INC75525N107COM383,638$23,850,774dollars as filed
PHARVARIS NVN69605108COMMON STOCK800,000$22,440,000dollars as filed
C4 THERAPEUTICS INC12529R107COM STK3,800,000$21,470,000dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,895,003$20,276,532dollars as filed
NKARTA INC65487U108COMMON STOCK2,730,000$18,018,000dollars as filed
KURA ONCOLOGY INC COM50127T109Stock1,248,062$17,947,132dollars as filed
HARPOON THERAPEUTICS INC41358P205COM1,500,000$17,055,000dollars as filed
AKERO THERAPEUTICS INC00973Y108COM565,000$13,192,750dollars as filed
SAB BIOTHERAPEUTICS INC78397T202COMMON STOCK1,831,746$12,593,254dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock900,000$11,970,000dollars as filed
VISTAGEN THERAPEUTICS INC92840H400COM1,575,000$8,095,500dollars as filed
THIRD HARMONIC BIO INC88427A107COM706,706$7,752,565dollars as filed
Adverum Biotechnologies, Inc.00773U108Common Stock10,000,000$7,528,000dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock250,000$6,985,000dollars as filed
DBV TECHNOLOGIES S A23306J101ADR92,687$88,312dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-24-000002this filing2024-02-14acceptance time not in the bulk data set
13F-HR/A 0001831942-24-000003 base2024-02-14acceptance time not in the bulk data set